HAIER BIOMEDICAL(SH:688139) Zhong Guo Ji Jin Bao·2025-10-15 16:16Core Viewpoint - Haier Biomedical has been targeted by Qindao Jiushi Investment Management Co., Ltd. through its private equity fund, Jiushi Preferred No. 1, which has acquired a 5% stake in the company, marking a significant investment after four years of stock price decline [2][4][12]. Group 1: Investment Details - Jiushi Preferred No. 1 acquired 15,897,909 shares of Haier Biomedical, representing 5% of the total share capital, through secondary market transactions from August 14, 2024, to October 14, 2025 [4][6]. - The investment was made using self-owned funds, and there are no immediate plans to increase or decrease the stake in the next 12 months [6][8]. Group 2: Company Background - Haier Biomedical is a subsidiary of Haier Group's health ecosystem brand, Yingkang Yisheng, established in October 2005 and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [13]. - The company has faced a continuous decline in stock price over the past four years, with significant drops of 29.83%, 35.46%, 12%, and 6.38% in 2022, 2023, 2024, and 2025 respectively [12][14]. Group 3: Financial Performance - In the first half of 2025, Haier Biomedical reported revenue of 1.196 billion yuan, a year-on-year decrease of 2.27%, and a net profit attributable to shareholders of 143 million yuan, down 39.09% year-on-year [14]. - The company noted that its new industries are growing well, contributing to 47% of total revenue, with significant growth in overseas business, which saw a 30.17% increase year-on-year [14].